Blocking and reversing liver fibrosis with traditional Chinese medicine compound prescriptions: Beyond the known frontiers
10.3969/j.issn.1001-5256.2023.02.004
- VernacularTitle:复方中药阻断逆转肝纤维化：超越已知的前沿
- Author:
Zhaofang BAI
1
,
2
;
Xiaoyan ZHAN
1
,
2
;
Guiji LYU
1
,
2
;
Yongping YANG
1
Author Information
1. Department of Hepatology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
2. China Military Institute of Chinese Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
- Publication Type:Discussions by Experts
- Keywords:
Hepatitis B, Chronic;
Liver Fibrosis;
Drugs, Chinese Herbal;
Biejia-Ruangan compound
- From:
Journal of Clinical Hepatology
2023;39(2):273-277
- CountryChina
- Language:Chinese
-
Abstract:
Liver fibrosis is the inevitable course for the progression of chronic hepatitis B to liver cirrhosis and is also the most important risk factor for hepatocarcinogenesis, and therefore, blocking and reversing liver fibrosis is an important strategy to effectively reduce the development of chronic hepatitis B cirrhosis and liver cancer. There are currently no effective drugs and measures for the treatment of liver fibrosis in Western medicine, and traditional Chinese medicine (TCM) has unique advantages in the treatment of liver fibrosis; however, due to a lack of strict and standardized clinical research, there is still no high-quality evidence for support from the aspect of evidence-based medicine (EBM). With subsidies from National Science and Technology Major Project in the 12th and 13th five-year plans, the authors conducted a multicenter, randomized, double-blind, placebo-controlled clinical trial on compound Biejia Ruangan tablets combined with entecavir in blocking and reversing chronic hepatitis B liver fibrosis. With liver biopsy as the gold standard, 1000 patients were enrolled to confirm the efficacy of compound Biejia Ruangan tablets combined with entecavir in blocking and reversing liver fibrosis and cirrhosis, and this study has become the first clinical trial investigating the anti-liver fibrosis effect of TCM supported by high-quality EBM evidence, bringing great hope to patients with chronic liver diseases and helping TCM move towards the world. This article introduces these research findings and reviews the current status and challenges of TCM in blocking and reversing liver fibrosis.
